Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 230.4	$ 64.8
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	96.5	75.0
Share based compensation	26.2	16.6
Change in fair value of contingent consideration	(59.2)	1.8
Goodwill impairment charge	0	7.1
Unwind of inventory fair value step up for products sold	38.8	0
Impairment of IPR&D intangible assets	166.0	0
Impairment of Property, Plant and Equipment ("PP&E")	12.1	0
Gain on sale of product rights	(36.4)	(6.5)
Other, net	(2.2)	0.1
Movement in deferred taxes	18.5	1.4
Equity in losses/(earnings) of equity method investees	0.6	(0.4)
Changes in operating assets and liabilities:
Increase in accounts receivable	(77.3)	(51.3)
Increase in sales deduction accruals	70.8	44.4
Increase in inventory	(18.6)	(29.1)
Increase in prepayments and other assets	(74.6)	(61.8)
Decrease in accounts and notes payable and other liabilities	(145.5)	(93.5)
Net cash provided by operating activities	246.1	160.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	(10.1)	(2.2)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(3,764.4)	(77.2)
Purchases of non-current investments and PP&E	(15.6)	(50.1)
Proceeds from short-term investments	46.8	0
Proceeds received on sale of product rights	48.0	4.8
Proceeds from capital expenditure grants	0	2.7
Proceeds from disposal of non-current investments and PP&E	8.0	0.7
Other, net	(2.9)	0
Net cash used in investing activities	(3,690.2)	(121.3)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long-term and short-term borrowings	2,170.0	0
Repayment of short term borrowings	(650.2)	0
Repayment of debt acquired with ViroPharma	(533.9)	0
Proceeds from ViroPharma call options	346.7	0
Payments to acquire shares under the share buy-back program (in USD)	0	(70.6)
Contingent consideration payments	(7.8)	(6.0)
Excess tax benefit associated with exercise of stock options	20.5	4.4
Other, net	0.2	(0.7)
Net cash provided by/(used in) financing activities	1,345.5	(72.9)
Effect of foreign exchange rate changes on cash and cash equivalents	(1.7)	2.3
Net decrease in cash and cash equivalents	(2,100.3)	(31.5)
Cash and cash equivalents at beginning of period	2,239.4	1,482.2
Cash and cash equivalents at end of period	139.1	1,450.7
Supplemental information associated with continuing operations:
Interest paid	(2.6)	(1.0)
Income taxes paid	(82.6)	(96.1)
Continung operations
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge		7.1
Discontinued operations
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge		191.8
Goowill impairment charge total
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge	$ 0	$ 198.9